Personal information

Other IDs

Scopus Author ID: 24280778600

Activities

Collapse all

Works (50 of 92)

Items per page:
Page 1 of 2

Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE

Digestive and Liver Disease
2025-01 | Journal article
DOI: 10.1016/j.dld.2024.06.022
Contributors: Chloé Buchalet; Claire Lemanski; Pascal Pommier; Karine Le Malicot; Nathalie Bonichon-Lamichhane; Ludovic Evesque; Olivia Diaz; Philippe Ronchin; Laurent Quero; Eleonor Rivin Del Campo et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

The oncologist
2024 | Journal article
DOI: 10.1093/oncolo/oyae079
EID:

2-s2.0-85203474486

Part of ISSN: 1549490X
Contributors: Boisteau, E.; Dahan, L.; Williet, N.; Le Malicot, K.; Desramé, J.; Bouché, O.; Petorin, C.; Malka, D.; Rebischung, C.; Aparicio, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Efficacy and Toxicity of (Chemo)Radiation Therapy in HIV+ Patients with Squamous Cell Anal Cancer, a Subgroup Analysis of the National Multicenter Cohort FFCD-ANABASE

International Journal of Radiation Oncology Biology Physics
2024 | Journal article
DOI: 10.1016/j.ijrobp.2024.04.067
EID:

2-s2.0-85196657561

Part of ISSN: 1879355X 03603016
Contributors: Evin, C.; Quéro, L.; Le Malicot, K.; Blanchet-Deverly, S.; Evesque, L.; Buchalet, C.; Lemanski, C.; Hamed, N.B.; Rivin del Campo, E.; Bauwens, L. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)

Cancers
2024 | Journal article
DOI: 10.3390/cancers16081515
EID:

2-s2.0-85191418502

Part of ISSN: 20726694
Contributors: Legoux, J.-L.; Faroux, R.; Barrière, N.; Le Malicot, K.; Tougeron, D.; Lorgis, V.; Guerin-Meyer, V.; Bourgeois, V.; Malka, D.; Aparicio, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 3)‎

FOLFIRI Plus Durvalumab with or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

JAMA Oncology
2024 | Journal article
DOI: 10.1001/jamaoncol.2024.0207
EID:

2-s2.0-85190307689

Part of ISSN: 23742445 23742437
Contributors: Tougeron, D.; Dahan, L.; Evesque, L.; Le Malicot, K.; El Hajbi, F.; Aparicio, T.; Bouché, O.; Bonichon Lamichhane, N.; Chibaudel, B.; Angelergues, A. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE

British Journal of Cancer
2024 | Journal article
DOI: 10.1038/s41416-023-02564-9
EID:

2-s2.0-85181452844

Part of ISSN: 15321827 00070920
Contributors: Gouriou, C.; Lemanski, C.; Pommier, P.; Le Malicot, K.; Saint, A.; Rivin del Campo, E.; Evin, C.; Quero, L.; Regnault, P.; Baba-Hamed, N. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

Clinical and Translational Radiation Oncology
2024 | Journal article
DOI: 10.1016/j.ctro.2024.100804
EID:

2-s2.0-85195608697

Part of ISSN: 24056308
Contributors: de Rauglaudre, B.; Piessen, G.; Jary, M.; Le Malicot, K.; Adenis, A.; Mazard, T.; D'Journo, X.B.; Petorin, C.; Buffet-Miny, J.; Aparicio, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Prognostic Value of <sup>18</sup>F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2024 | Journal article
DOI: 10.2967/jnumed.124.267626
EID:

2-s2.0-85200525402

Part of ISSN: 15355667
Contributors: Combet-Curt, V.; Buchalet, C.; Le Malicot, K.; Lemanski, C.; Deshayes, E.; Bonichon-Lamichhane, N.; Lièvre, A.; Huguet, F.; Tlili, G.; Vendrely, V.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer

Digestive and Liver Disease
2024 | Journal article
DOI: 10.1016/j.dld.2024.05.014
EID:

2-s2.0-85195379505

Part of ISSN: 18783562 15908658
Contributors: Hoba, J.; Grancher, A.; Hautefeuille, V.; Turpin, A.; Bouhier-Leporrier, K.; Galais, M.-P.; Bignon, A.-L.; Di Fiore, A.; Desgrippes, R.; Miglianico, L. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort

ESMO Open
2024-12 | Journal article
DOI: 10.1016/j.esmoop.2024.103988
Contributors: G. Roth; A. Pellat; G. Piessen; K. le Malicot; L. Schwarz; C. Gallois; D. Tougeron; V. Hautefeuille; M. Jary; S. Benoist et al.
Source: check_circle
Crossref

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology

Current Oncology
2024-06 | Journal article | Author
DOI: 10.3390/curroncol31060259
Contributors: Elodie Martin; Karine Le Malicot; Catherine GUERIN-CHARBONNEL; François Bocquet; Olivier BOUCHE; Anthony Turpin; Thomas APARICIO; Jean-Louis Legoux; Laetitia Dahan; Julien Taieb et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 3)‎

Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

JAMA Oncology
2023 | Journal article
DOI: 10.1001/jamaoncol.2023.2761
EID:

2-s2.0-85175256452

Part of ISSN: 23742445 23742437
Contributors: Taïeb, J.; Bouche, O.; André, T.; Le Malicot, K.; Laurent-Puig, P.; Bez, J.; Toullec, C.; Borg, C.; Randrian, V.; Evesque, L. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

The Lancet Oncology
2023 | Journal article
DOI: 10.1016/S1470-2045(23)00001-3
EID:

2-s2.0-85149174465

Part of ISSN: 14745488 14702045
Contributors: Walter, T.; Lievre, A.; Coriat, R.; Malka, D.; Elhajbi, F.; Di Fiore, F.; Hentic, O.; Smith, D.; Hautefeuille, V.; Roquin, G. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial

Digestive and Liver Disease
2023 | Journal article
DOI: 10.1016/j.dld.2022.12.018
EID:

2-s2.0-85147455887

Part of ISSN: 18783562 15908658
Contributors: Salfati, D.; Huot, M.; Aparicio, T.; Lepage, C.; Taieb, J.; Bouché, O.; Boige, V.; Phelip, J.-M.; Dahan, L.; Bennouna, J. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

Experimental Hematology and Oncology
2023 | Journal article
DOI: 10.1186/s40164-023-00413-2
EID:

2-s2.0-85165372305

Part of ISSN: 21623619
Contributors: Kim, S.; Vendrely, V.; Saint, A.; André, T.; Vaflard, P.; Samalin, E.; Pernot, S.; Bouché, O.; Zubir, M.; Desrame, J. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

ESMO Open
2023 | Journal article
DOI: 10.1016/j.esmoop.2023.101616
EID:

2-s2.0-85166657700

Part of ISSN: 20597029
Contributors: du Rusquec, P.; Guimbaud, R.; Le Malicot, K.; Gornet, J.-M.; Nguyen, S.; Lecomte, T.; Khemissa-Akouz, F.; Perrier, H.; Bouché, O.; Paoletti, X. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Digestive and Liver Disease
2023 | Journal article
DOI: 10.1016/j.dld.2023.01.161
EID:

2-s2.0-85148369226

Part of ISSN: 18783562 15908658
Contributors: Merle, P.; Blanc, J.-F.; Edeline, J.; Le Malicot, K.; Allaire, M.; Assenat, E.; Guarssifi, M.; Bouattour, M.; Péron, J.-M.; Laurent-Puig, P. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial

Radiotherapy and Oncology
2023 | Journal article
DOI: 10.1016/j.radonc.2023.109742
EID:

2-s2.0-85163172459

Part of ISSN: 18790887 01678140
Contributors: Vendrely, V.; Ronchin, P.; Minsat, M.; Le Malicot, K.; Lemanski, C.; Mirabel, X.; Etienne, P.-L.; Lièvre, A.; Darut-Jouve, A.; de la Fouchardière, C. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Radiotherapy and Oncology
2023 | Journal article
DOI: 10.1016/j.radonc.2023.109542
EID:

2-s2.0-85149419298

Part of ISSN: 18790887 01678140
Contributors: VENDRELY, V.; LEMANSKI, C.; POMMIER, P.; LE MALICOT, K.; SAINT, A.; RIVIN DEL CAMPO, E.; REGNAULT, P.; BABA-HAMED, N.; RONCHIN, P.; CREHANGE, G. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530403
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530403.v1
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480257
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480254.v1
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480257.v1
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480254
Contributors: Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval et al.
Source: check_circle
Crossref

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer

European Journal of Cancer
2022 | Journal article
DOI: 10.1016/j.ejca.2022.05.040
EID:

2-s2.0-85133364526

Part of ISSN: 18790852 09598049
Contributors: Derangère, V.; Lecuelle, J.; Lepage, C.; Aoulad-Ben Salem, O.; Allatessem, B.M.; Ilie, A.; Bouché, O.; Phelip, J.-M.; Baconnier, M.; Pezet, D. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

BMC Cancer
2022 | Journal article
DOI: 10.1186/s12885-022-09806-8
EID:

2-s2.0-85133575593

Part of ISSN: 14712407
Contributors: Kerckhove, N.; Tougeron, D.; Lepage, C.; Pezet, D.; Le Malicot, K.; Pelkowski, M.; Pereira, B.; Balayssac, D.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer

Digestive and Liver Disease
2022 | Journal article
DOI: 10.1016/j.dld.2022.04.024
EID:

2-s2.0-85130575979

Part of ISSN: 18783562 15908658
Contributors: Randrian, V.; Pernot, S.; Le Malicot, K.; Catena, V.; Baumgaertner, I.; Tacher, V.; Forestier, J.; Hautefeuille, V.; Tabouret-Viaud, C.; Gagnaire, A. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—A pooled analysis of three adjuvant trials

European Journal of Cancer
2022 | Journal article
DOI: 10.1016/j.ejca.2022.02.005
EID:

2-s2.0-85126020801

Part of ISSN: 18790852 09598049
Contributors: Christou, N.; Bergen, E.S.; Canton, C.; Le Malicot, K.; Di Bartolomeo, M.; Galli, F.; Galli, F.; Labianca, R.; Shi, Q.; Alberts, S.R. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

Oncologist
2022 | Journal article
DOI: 10.1093/oncolo/oyac055
EID:

2-s2.0-85134084220

Part of ISSN: 1549490X 10837159
Contributors: Canton, C.; Boussari, O.; Boulin, M.; Le Malicot, K.; Taieb, J.; Dahan, L.; Lopez, A.; Lepage, C.; Bachet, J.-B.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

European Journal of Cancer
2022 | Journal article
DOI: 10.1016/j.ejca.2022.07.033
EID:

2-s2.0-85137410259

Part of ISSN: 18790852 09598049
Contributors: Lepage, C.; Phelip, J.-M.; Lievre, A.; Le-Malicot, K.; Dahan, L.; Tougeron, D.; Toumpanakis, C.; Di-Fiore, F.; Lombard-Bohas, C.; Borbath, I. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

Frontiers in Oncology
2022 | Journal article
DOI: 10.3389/fonc.2022.973167
EID:

2-s2.0-85142650668

Part of ISSN: 2234943X
Contributors: Grancher, A.; Beaussire, L.; Manfredi, S.; Le Malicot, K.; Dutherage, M.; Verdier, V.; Mulot, C.; Bouché, O.; Phelip, J.-M.; Levaché, C.-B. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Therapeutic Advances in Medical Oncology
2022 | Journal article
DOI: 10.1177/17588359221141307
EID:

2-s2.0-85144930127

Part of ISSN: 17588359 17588340
Contributors: de Rauglaudre, B.; Sibertin-Blanc, C.; Fabre, A.; Le Malicot, K.; Bennouna, J.; Ghiringhelli, F.; Taïeb, J.; Boige, V.; Bouché, O.; Chatellier, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

Biomedicines
2022 | Journal article
DOI: 10.3390/biomedicines10051211
EID:

2-s2.0-85131561115

Part of ISSN: 22279059
Contributors: Evrard, C.; Aparicio, T.; Soularue, E.; Le Malicot, K.; Desramé, J.; Botsen, D.; El Hajbi, F.; Gonzalez, D.; Lepage, C.; Bouché, O. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

Digestive and Liver Disease
2022 | Journal article
DOI: 10.1016/j.dld.2022.03.001
EID:

2-s2.0-85127305231

Part of ISSN: 18783562 15908658
Contributors: Boisteau, E.; François, E.; Aparicio, T.; Le Malicot, K.; Boulahssass, R.; Lecomte, T.; Laurent-Puig, P.; Guiu, B.; Paillaud, E.; Galais, M.-P. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies

Cancer Treatment Reviews
2021 | Journal article
DOI: 10.1016/j.ctrv.2021.102202
EID:

2-s2.0-85103952269

Part of ISSN: 15321967 03057372
Contributors: Salvatore, L.; Bria, E.; Sperduti, I.; Hinke, A.; Hegewisch-Becker, S.; Aparicio, T.; Le Malicot, K.; Boige, V.; Koeberle, D.; Baertschi, D. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial

Digestive and Liver Disease
2021 | Journal article
DOI: 10.1016/j.dld.2021.05.012
EID:

2-s2.0-85107577457

Part of ISSN: 18783562 15908658
Contributors: Voron, T.; Karoui, M.; Lo Dico, R.; Malicot, K.L.; Espin, E.; Cianchi, F.; Jürgen, W.; Buggenhout, A.; Bruzzi, M.; Denimal, F. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

BMC Medical Research Methodology
2021 | Journal article
DOI: 10.1186/s12874-020-01202-9
EID:

2-s2.0-85098954459

Part of ISSN: 14712288
Contributors: Guilloteau, A.; Abrahamowicz, M.; Boussari, O.; Jooste, V.; Aparicio, T.; Quantin, C.; Le Malicot, K.; Binquet, C.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer

Clinical Cancer Research
2021 | Journal article
DOI: 10.1158/1078-0432.CCR-21-0529
EID:

2-s2.0-85114134277

Part of ISSN: 15573265 10780432
Contributors: Marisa, L.; Blum, Y.; Taieb, J.; Ayadi, M.; Pilati, C.; Le Malicot, K.; Lepage, C.; Salazar, R.; Aust, D.; Duval, A. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

Clinics and Research in Hepatology and Gastroenterology
2021 | Journal article
DOI: 10.1016/j.clinre.2020.05.012
EID:

2-s2.0-85086863039

Part of ISSN: 2210741X 22107401
Contributors: Turpin, A.; de Baere, T.; Heurgué, A.; Le Malicot, K.; Ollivier-Hourmand, I.; Lecomte, T.; Perrier, H.; Vergniol, J.; Sefrioui, D.; Rinaldi, Y. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery

Acta Oncologica
2021 | Journal article
DOI: 10.1080/0284186X.2021.1944662
EID:

2-s2.0-85109326378

Part of ISSN: 1651226X 0284186X
Contributors: Terlizzi, M.; Buscail, E.; Boussari, O.; Adgié, S.; Leduc, N.; Terrebonne, E.; Smith, D.; Blanc, J.-F.; Lapuyade, B.; Laurent, C. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials

European Journal of Cancer
2021 | Journal article
DOI: 10.1016/j.ejca.2021.04.040
EID:

2-s2.0-85107784968

Part of ISSN: 18790852 09598049
Contributors: Breton, C.; Aparicio, T.; Le Malicot, K.; Ducreux, M.; Lecomte, T.; Bachet, J.-B.; Taieb, J.; Legoux, J.-L.; De Gramont, A.; Benouna, J. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Digestive and Liver Disease
2021 | Journal article
DOI: 10.1016/j.dld.2020.11.036
EID:

2-s2.0-85098061349

Part of ISSN: 18783562 15908658
Contributors: Evrard, C.; Louvet, C.; Hajbi, F.E.; Fiore, F.D.; Malicot, K.L.; Aparicio, T.; Bouché, O.; Laurent-Puig, P.; Bibeau, F.; Lecomte, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

British Journal of Cancer
2021 | Journal article
DOI: 10.1038/s41416-021-01624-2
EID:

2-s2.0-85119660484

Part of ISSN: 15321827 00070920
Contributors: Pietrasz, D.; Wang-Renault, S.; Taieb, J.; Dahan, L.; Postel, M.; Durand-Labrunie, J.; Le Malicot, K.; Mulot, C.; Rinaldi, Y.; Phelip, J.-M. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Prognostic value of the PrP<sup>C</sup>-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype

OncoImmunology
2021 | Journal article
DOI: 10.1080/2162402X.2021.1940674
EID:

2-s2.0-85108840374

Part of ISSN: 2162402X 21624011
Contributors: Ghazi, A.; Le Corre, D.; Pilati, C.; Taieb, J.; Aparicio, T.; Didelot, A.; Dedhar, S.; Mulot, C.; Le Malicot, K.; Djouadi, F. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials

European Journal of Cancer
2021 | Journal article
DOI: 10.1016/j.ejca.2020.11.016
EID:

2-s2.0-85097756619

Part of ISSN: 18790852 09598049
Contributors: Sinicrope, F.A.; Chakrabarti, S.; Laurent-Puig, P.; Huebner, L.; Smyrk, T.C.; Tabernero, J.; Mini, E.; Goldberg, R.M.; Zaanan, A.; Folprecht, G. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Journal of Clinical Oncology
2021 | Journal article
DOI: 10.1200/JCO.20.03329
EID:

2-s2.0-85117968028

Part of ISSN: 15277755 0732183X
Contributors: Dahan, L.; Williet, N.; Le Malicot, K.; Phelip, J.-M.; Desrame, J.; Bouché, O.; Petorin, C.; Malka, D.; Rebischung, C.; Aparicio, T. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
grade
Preferred source (of 2)‎

Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study

Clinics and Research in Hepatology and Gastroenterology
2021 | Journal article
DOI: 10.1016/j.clinre.2020.10.014
EID:

2-s2.0-85103003612

Part of ISSN: 2210741X 22107401
Contributors: Legoux, J.-L.; Lombard-Bohas, C.; Brixi, H.; Le Malicot, K.; Lecomte, T.; Dahan, L.; Ruszniewski, P.; Mahamat-Abakar, A.; Etienne, P.-L.; Caroli-Bosc, F.-X. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)

Clinical Colorectal Cancer
2020 | Journal article
DOI: 10.1016/j.clcc.2020.06.003
EID:

2-s2.0-85090737113

Part of ISSN: 19380674 15330028
Contributors: Lapeyre-Prost, A.; Pernot, S.; Sigrand, J.; Le Malicot, K.; Mary, F.; Aparicio, T.; Dahan, L.; Caroli-Bosc, F.-X.; Lecomte, T.; Doat, S. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study

Gut
2020 | Journal article
DOI: 10.1136/gutjnl-2019-319292
EID:

2-s2.0-85075874556

Part of ISSN: 14683288 00175749
Contributors: Reichling, C.; Taieb, J.; Derangere, V.; Klopfenstein, Q.; Le Malicot, K.; Gornet, J.-M.; Becheur, H.; Fein, F.; Cojocarasu, O.; Kaminsky, M.C. et al.
Source: Self-asserted source
Karine Le Malicot via Scopus - Elsevier
Items per page:
Page 1 of 2
How many people are using ORCID?